{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:51:12Z","timestamp":1789753872021,"version":"4.0.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:00:00Z","timestamp":1666483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:00:00Z","timestamp":1666483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected non-human primates (NHPs) from SARS-CoV-2 WA-1 infection. Here, we find the RBD-scNP induced neutralizing antibodies in NHPs against pseudoviruses of SARS-CoV and SARS-CoV-2 variants including 614G, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, and BA.4\/BA.5, and a designed variant with escape mutations, PMS20. Adjuvant studies demonstrate variant neutralization titers are highest with 3M-052-aqueous formulation (AF). Immunization twice with RBD-scNPs protect NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protect mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants.<\/jats:p>","DOI":"10.1038\/s41467-022-33985-4","type":"journal-article","created":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T02:02:59Z","timestamp":1666490579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine"],"prefix":"10.1038","volume":"13","author":[{"given":"Dapeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2940-8961","authenticated-orcid":false,"given":"David R.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4760-4923","authenticated-orcid":false,"given":"Alexandra","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2182-0510","authenticated-orcid":false,"given":"Dieter","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9454-0937","authenticated-orcid":false,"given":"Kevin W.","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Minai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca M.","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-6162","authenticated-orcid":false,"given":"Matthew","family":"Gagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Douek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Todd","family":"DeMarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Thomas H.","family":"Oguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alecia","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wes","family":"Rountree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4446-1194","authenticated-orcid":false,"given":"Robert J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-6594","authenticated-orcid":false,"given":"Gregory D.","family":"Sempowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3064-2947","authenticated-orcid":false,"given":"Amanda","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek W.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8796-1714","authenticated-orcid":false,"given":"Sampa","family":"Santra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Tomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1103-9608","authenticated-orcid":false,"given":"Hanne","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7852-0135","authenticated-orcid":false,"given":"Mark G.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Golding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3133-0849","authenticated-orcid":false,"given":"Robert","family":"Seder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-7965","authenticated-orcid":false,"given":"Surender","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8701","authenticated-orcid":false,"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7399-7954","authenticated-orcid":false,"given":"Kevin O.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton F.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,23]]},"reference":[{"key":"33985_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Disco. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Disco."},{"key":"33985_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug Disco. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Disco."},{"key":"33985_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","volume":"65","author":"N Pardi","year":"2020","unstructured":"Pardi, N., Hogan, M. J. & Weissman, D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14\u201320 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"33985_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"33985_CR5","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"33985_CR6","doi-asserted-by":"publisher","unstructured":"Wang, L. & Cheng, G. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. J. Med. Virol., https:\/\/doi.org\/10.1002\/jmv.27516 (2021).","DOI":"10.1002\/jmv.27516"},{"key":"33985_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","volume":"603","author":"R Viana","year":"2022","unstructured":"Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679\u2013686 (2022).","journal-title":"Nature"},{"key":"33985_CR8","doi-asserted-by":"publisher","unstructured":"Yamasoba, D. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell, https:\/\/doi.org\/10.1016\/j.cell.2022.04.035 (2022).","DOI":"10.1016\/j.cell.2022.04.035"},{"key":"33985_CR9","doi-asserted-by":"publisher","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. bioRxiv https:\/\/doi.org\/10.1101\/2022.04.30.489997 (2022).","DOI":"10.1101\/2022.04.30.489997"},{"key":"33985_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-021-03594-0","volume":"594","author":"KO Saunders","year":"2021","unstructured":"Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553\u2013559 (2021).","journal-title":"Nature"},{"key":"33985_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","volume":"600","author":"F Schmidt","year":"2021","unstructured":"Schmidt, F. et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 600, 512\u2013516 (2021).","journal-title":"Nature"},{"key":"33985_CR12","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1016\/j.cell.2021.06.021","volume":"184","author":"D Li","year":"2021","unstructured":"Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 184, 4203\u20134219 e4232 (2021).","journal-title":"Cell"},{"key":"33985_CR13","doi-asserted-by":"publisher","unstructured":"Li, D., Sempowski, G. D., Saunders, K. O., Acharya, P.& Haynes, B. F. SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. Annu. Rev. Med., https:\/\/doi.org\/10.1146\/annurev-med-042420-113838 (2021).","DOI":"10.1146\/annurev-med-042420-113838"},{"key":"33985_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.abh2315","volume":"374","author":"KM Hastie","year":"2021","unstructured":"Hastie, K. M. et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science 374, 472\u2013478 (2021).","journal-title":"Science"},{"key":"33985_CR15","doi-asserted-by":"crossref","unstructured":"Martinez, D. R. et al. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Sci. Transl. Med., 14, eabj7125 (2021).","DOI":"10.1126\/scitranslmed.abj7125"},{"key":"33985_CR16","doi-asserted-by":"publisher","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","volume":"373","author":"KS Corbett","year":"2021","unstructured":"Corbett, K. S. et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373, eabj0299 (2021).","journal-title":"Science"},{"key":"33985_CR17","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040 (2021).","journal-title":"Nat. Med."},{"key":"33985_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"33985_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"33985_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042.e1021 (2020).","journal-title":"Cell"},{"key":"33985_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650\u2013655 (2020).","journal-title":"Science"},{"key":"33985_CR22","doi-asserted-by":"publisher","unstructured":"McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell, https:\/\/doi.org\/10.1016\/j.cell.2021.03.028 (2021).","DOI":"10.1016\/j.cell.2021.03.028"},{"key":"33985_CR23","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","volume":"185","author":"M Gagne","year":"2022","unstructured":"Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 185, 1556\u20131571.e1518 (2022).","journal-title":"Cell"},{"key":"33985_CR24","doi-asserted-by":"publisher","unstructured":"Muecksch, F. et al. Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost. Nature, https:\/\/doi.org\/10.1038\/s41586-022-04778-y (2022).","DOI":"10.1038\/s41586-022-04778-y"},{"key":"33985_CR25","doi-asserted-by":"publisher","unstructured":"Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, https:\/\/doi.org\/10.1038\/s41586-021-04386-2 (2021).","DOI":"10.1038\/s41586-021-04386-2"},{"key":"33985_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"33985_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJMc2206576","volume":"387","author":"NP Hachmann","year":"2022","unstructured":"Hachmann, N. P. et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 387, 86\u201388 (2022).","journal-title":"N. Engl. J. Med"},{"key":"33985_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","volume":"28","author":"E Perez-Then","year":"2022","unstructured":"Perez-Then, E. et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat. Med. 28, 481\u2013485 (2022).","journal-title":"Nat. Med"},{"key":"33985_CR29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492\u2013503 (2010).","journal-title":"Immunity"},{"key":"33985_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0089-x","volume":"3","author":"H HogenEsch","year":"2018","unstructured":"HogenEsch, H., O\u2019Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 3, 51 (2018).","journal-title":"NPJ Vaccines"},{"key":"33985_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23942-y","volume":"12","author":"NK Routhu","year":"2021","unstructured":"Routhu, N. K. et al. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nat. Commun. 12, 3587 (2021).","journal-title":"Nat. Commun."},{"key":"33985_CR32","doi-asserted-by":"publisher","unstructured":"Kasturi, S. P. et al. 3M-052, a synthetic TLR-7\/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Sci. Immunol. 5, https:\/\/doi.org\/10.1126\/sciimmunol.abb1025 (2020).","DOI":"10.1126\/sciimmunol.abb1025"},{"key":"33985_CR33","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","volume":"29","author":"D Smirnov","year":"2011","unstructured":"Smirnov, D., Schmidt, J. J., Capecchi, J. T. & Wightman, P. D. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29, 5434\u20135442 (2011).","journal-title":"Vaccine"},{"key":"33985_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack, P., McKee, A. S. & Munks, M. W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9, 287\u2013293 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"33985_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2016.11.011","volume":"244","author":"CB Fox","year":"2016","unstructured":"Fox, C. B. et al. Adsorption of a synthetic TLR7\/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. J. Control Release 244, 98\u2013107 (2016).","journal-title":"J. Control Release"},{"key":"33985_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2051013613480144","volume":"1","author":"CB Fox","year":"2013","unstructured":"Fox, C. B., Kramer, R. M., Barnes, V. L., Dowling, Q. M. & Vedvick, T. S. Working together: interactions between vaccine antigens and adjuvants. Ther. Adv. Vaccines 1, 7\u201320 (2013).","journal-title":"Ther. Adv. Vaccines"},{"key":"33985_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","volume":"584","author":"AM Arvin","year":"2020","unstructured":"Arvin, A. M. et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 584, 353\u2013363 (2020).","journal-title":"Nature"},{"key":"33985_CR38","doi-asserted-by":"publisher","unstructured":"Haynes, B. F. et al. Prospects for a safe COVID-19 vaccine. Sci. Transl. Med. 12, https:\/\/doi.org\/10.1126\/scitranslmed.abe0948 (2020).","DOI":"10.1126\/scitranslmed.abe0948"},{"key":"33985_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell 182, 722\u2013733.e711 (2020).","journal-title":"Cell"},{"key":"33985_CR40","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","volume":"586","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572\u2013577 (2020).","journal-title":"Nature"},{"key":"33985_CR41","doi-asserted-by":"publisher","unstructured":"Francica, J. R. et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci. Transl. Med. 13, https:\/\/doi.org\/10.1126\/scitranslmed.abi4547 (2021).","DOI":"10.1126\/scitranslmed.abi4547"},{"key":"33985_CR42","doi-asserted-by":"publisher","unstructured":"Pino, M. et al. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci. Immunol. 6, https:\/\/doi.org\/10.1126\/sciimmunol.abh3634 (2021).","DOI":"10.1126\/sciimmunol.abh3634"},{"key":"33985_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"33985_CR44","doi-asserted-by":"publisher","unstructured":"Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe, https:\/\/doi.org\/10.1016\/j.chom.2021.03.005 (2021).","DOI":"10.1016\/j.chom.2021.03.005"},{"key":"33985_CR45","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1126\/science.abi4506","volume":"373","author":"DR Martinez","year":"2021","unstructured":"Martinez, D. R. et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science 373, 991\u2013998 (2021).","journal-title":"Science"},{"key":"33985_CR46","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"33985_CR47","doi-asserted-by":"publisher","first-page":"108322","DOI":"10.1016\/j.celrep.2020.108322","volume":"33","author":"T Zhou","year":"2020","unstructured":"Zhou, T. et al. Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike molecular probes. Cell Rep. 33, 108322 (2020).","journal-title":"Cell Rep."},{"key":"33985_CR48","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A multi-targeting, nucleoside-modified mrna influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569\u20131584 (2020).","journal-title":"Mol. Ther."},{"key":"33985_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.omtm.2021.06.003","volume":"22","author":"AW Freyn","year":"2021","unstructured":"Freyn, A. W. et al. Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Mol. Ther. Methods Clin. Dev. 22, 84\u201395 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"33985_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersdorfer","year":"2019","unstructured":"Baiersdorfer, M. et al. A facile method for the removal of dsrna contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"33985_CR51","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"33985_CR52","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827.e819 (2020).","journal-title":"Cell"},{"key":"33985_CR53","doi-asserted-by":"publisher","first-page":"11382","DOI":"10.1073\/pnas.93.21.11382","volume":"93","author":"L Naldini","year":"1996","unstructured":"Naldini, L., Blomer, U., Gage, F. H., Trono, D. & Verma, I. M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl Acad. Sci. USA 93, 11382\u201311388 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"33985_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jviromet.2004.04.009","volume":"120","author":"JD Berry","year":"2004","unstructured":"Berry, J. D. et al. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J. Virol. Methods 120, 87\u201396 (2004).","journal-title":"J. Virol. Methods"},{"key":"33985_CR55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jim.2014.01.004","volume":"409","author":"AM Sanchez","year":"2014","unstructured":"Sanchez, A. M. et al. Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. J. Immunol. Methods 409, 117\u2013130 (2014).","journal-title":"J. Immunol. Methods"},{"key":"33985_CR56","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R Wolfel","year":"2020","unstructured":"Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465\u2013469 (2020).","journal-title":"Nature"},{"key":"33985_CR57","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"33985_CR58","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/nm.3985","volume":"21","author":"VD Menachery","year":"2015","unstructured":"Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508\u20131513 (2015).","journal-title":"Nat. Med"},{"key":"33985_CR59","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","volume":"183","author":"SR Leist","year":"2020","unstructured":"Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070\u20131085.e1012 (2020).","journal-title":"Cell"},{"key":"33985_CR60","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1371\/journal.ppat.0030005","volume":"3","author":"A Roberts","year":"2007","unstructured":"Roberts, A. et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB\/c mice. PLoS Pathog. 3, e5 (2007).","journal-title":"PLoS Pathog."},{"key":"33985_CR61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33985-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33985-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33985-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T06:44:30Z","timestamp":1728197070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33985-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,23]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33985"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33985-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.01.26.477915","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,23]]},"assertion":[{"value":"20 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.F.H. and K.O.S. have filed US patents regarding the nanoparticle vaccine, M.A.T. and the 3M company have US patents filed on 3M-052, and C.B.F. and IDRI have filed a patent on the formulation of 3M-052-AF and 3M-052-Alum. The 3M company had no role in the execution of the study, data collection or data interpretation. D.W. is named on US patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. D.W. and N.P. are also named on a US patent describing the use of nucleoside-modified mRNA in lipid nanoparticles as a vaccine platform. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6309"}}